^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    opevesostat (MK-5684)

    i
    Other names: MK-5684, ODM-208, ODM 208, ODM208, MK 5684, MK5684
    Company:
    Merck (MSD), Orion Corp
    Drug class:
    CYP11A1 inhibitor
    Related drugs:
    1d
    Safety and pharmacokinetics of odm-208 in patients with metastatic castration-resistant prostate cancer (2024-517439-39-00)
    P1/2, N=129, Completed, Orion Corporation | Active, not recruiting --> Completed
    Trial completion
    |
    opevesostat (MK-5684) • midazolam hydrochloride
    24d
    A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017) (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    prednisone • itraconazole • opevesostat (MK-5684)
    1m
    OMAHA-003: Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (clinicaltrials.gov)
    P3, N=1310, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Aug 2028 --> Feb 2030
    Trial completion date
    |
    enzalutamide • abiraterone acetate • prednisone • dexamethasone • opevesostat (MK-5684) • Yonsa (abiraterone acetate)
    2ms
    A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017) (clinicaltrials.gov)
    P1, N=14, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    prednisone • itraconazole • opevesostat (MK-5684)
    2ms
    A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005) (clinicaltrials.gov)
    P1, N=7, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    opevesostat (MK-5684)
    2ms
    A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017) (clinicaltrials.gov)
    P1, N=14, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1 trial
    |
    prednisone • itraconazole • opevesostat (MK-5684)
    2ms
    A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) (clinicaltrials.gov)
    P2, N=250, Recruiting, Merck Sharp & Dohme LLC
    Trial initiation date • Pan tumor
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    tamoxifen • fulvestrant • letrozole • exemestane • megestrol • opevesostat (MK-5684)
    3ms
    A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) (clinicaltrials.gov)
    P1/2, N=360, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2030 --> Apr 2031 | Trial primary completion date: Feb 2030 --> Apr 2031
    Trial completion date • Trial primary completion date
    |
    docetaxel • enzalutamide • abiraterone acetate • ifinatamab deruxtecan (DS-7300) • opevesostat (MK-5684)
    3ms
    OMAHA-004: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (clinicaltrials.gov)
    P3, N=1314, Active, not recruiting, Merck Sharp & Dohme LLC | Suspended --> Active, not recruiting
    Enrollment closed
    |
    enzalutamide • abiraterone acetate • prednisone • opevesostat (MK-5684)
    3ms
    A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) (clinicaltrials.gov)
    P1, N=14, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    opevesostat (MK-5684)
    4ms
    A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009) (clinicaltrials.gov)
    P1, N=16, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    prednisone • opevesostat (MK-5684)
    4ms
    A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Mar 2027 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    opevesostat (MK-5684)